Cargando…
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Synaptic degeneration and neuronal loss are early events in Alzheimer’s disease (AD), occurring long before symptom onset, thus making synaptic biomarkers relevant for enabling early diagnosis. The postsynaptic protein neurogranin (Ng) is a cerebrospinal fluid (CSF) biomarker for AD, also in the pro...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338696/ https://www.ncbi.nlm.nih.gov/pubmed/30244311 http://dx.doi.org/10.1007/s00401-018-1910-3 |
_version_ | 1783388473356451840 |
---|---|
author | Kvartsberg, Hlin Lashley, Tammaryn Murray, Christina E. Brinkmalm, Gunnar Cullen, Nicholas C. Höglund, Kina Zetterberg, Henrik Blennow, Kaj Portelius, Erik |
author_facet | Kvartsberg, Hlin Lashley, Tammaryn Murray, Christina E. Brinkmalm, Gunnar Cullen, Nicholas C. Höglund, Kina Zetterberg, Henrik Blennow, Kaj Portelius, Erik |
author_sort | Kvartsberg, Hlin |
collection | PubMed |
description | Synaptic degeneration and neuronal loss are early events in Alzheimer’s disease (AD), occurring long before symptom onset, thus making synaptic biomarkers relevant for enabling early diagnosis. The postsynaptic protein neurogranin (Ng) is a cerebrospinal fluid (CSF) biomarker for AD, also in the prodromal phase. Here we tested the hypothesis that during AD neurodegeneration, processing of full-length Ng into endogenous peptides in the brain is increased. We characterized Ng in post-mortem brain tissue and investigated the levels of endogenous Ng peptides in relation to full-length protein in brain tissue of patients with sporadic (sAD) and familial Alzheimer’s disease (fAD), healthy controls and individuals who were cognitively unaffected but amyloid-positive (CU-AP) in two different brain regions. Brain tissue from parietal cortex [sAD (n = 10) and age-matched controls (n = 10)] and temporal cortex [sAD (n = 9), fAD (n = 10), CU-AP (n = 13) and controls (n = 9)] were included and all the samples were analyzed by three different methods. Using high-resolution mass spectrometry, 39 endogenous Ng peptides were identified while full-length Ng was found to be modified including disulfide bridges or glutathione. In sAD parietal cortex, the ratio of peptide-to-total full-length Ng was significantly increased for eight endogenous Ng peptides compared to controls. In the temporal cortex, several of the peptide-to-total full-length Ng ratios were increased in both sAD and fAD cases compared to controls and CU-AP. This finding was confirmed by western blot, which mainly detects full-length Ng, and enzyme-linked immunosorbent assay, most likely detecting a mix of peptides and full-length Ng. In addition, Ng was significantly associated with the degree of amyloid and tau pathology. These results suggest that processing of Ng into peptides is increased in AD brain tissue, which may reflect the ongoing synaptic degeneration, and which is also mirrored as increased levels of Ng peptides in CSF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00401-018-1910-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6338696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-63386962019-02-01 The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease Kvartsberg, Hlin Lashley, Tammaryn Murray, Christina E. Brinkmalm, Gunnar Cullen, Nicholas C. Höglund, Kina Zetterberg, Henrik Blennow, Kaj Portelius, Erik Acta Neuropathol Original Paper Synaptic degeneration and neuronal loss are early events in Alzheimer’s disease (AD), occurring long before symptom onset, thus making synaptic biomarkers relevant for enabling early diagnosis. The postsynaptic protein neurogranin (Ng) is a cerebrospinal fluid (CSF) biomarker for AD, also in the prodromal phase. Here we tested the hypothesis that during AD neurodegeneration, processing of full-length Ng into endogenous peptides in the brain is increased. We characterized Ng in post-mortem brain tissue and investigated the levels of endogenous Ng peptides in relation to full-length protein in brain tissue of patients with sporadic (sAD) and familial Alzheimer’s disease (fAD), healthy controls and individuals who were cognitively unaffected but amyloid-positive (CU-AP) in two different brain regions. Brain tissue from parietal cortex [sAD (n = 10) and age-matched controls (n = 10)] and temporal cortex [sAD (n = 9), fAD (n = 10), CU-AP (n = 13) and controls (n = 9)] were included and all the samples were analyzed by three different methods. Using high-resolution mass spectrometry, 39 endogenous Ng peptides were identified while full-length Ng was found to be modified including disulfide bridges or glutathione. In sAD parietal cortex, the ratio of peptide-to-total full-length Ng was significantly increased for eight endogenous Ng peptides compared to controls. In the temporal cortex, several of the peptide-to-total full-length Ng ratios were increased in both sAD and fAD cases compared to controls and CU-AP. This finding was confirmed by western blot, which mainly detects full-length Ng, and enzyme-linked immunosorbent assay, most likely detecting a mix of peptides and full-length Ng. In addition, Ng was significantly associated with the degree of amyloid and tau pathology. These results suggest that processing of Ng into peptides is increased in AD brain tissue, which may reflect the ongoing synaptic degeneration, and which is also mirrored as increased levels of Ng peptides in CSF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00401-018-1910-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-09-22 2019 /pmc/articles/PMC6338696/ /pubmed/30244311 http://dx.doi.org/10.1007/s00401-018-1910-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Kvartsberg, Hlin Lashley, Tammaryn Murray, Christina E. Brinkmalm, Gunnar Cullen, Nicholas C. Höglund, Kina Zetterberg, Henrik Blennow, Kaj Portelius, Erik The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease |
title | The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease |
title_full | The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease |
title_fullStr | The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease |
title_full_unstemmed | The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease |
title_short | The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease |
title_sort | intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic alzheimer’s disease |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338696/ https://www.ncbi.nlm.nih.gov/pubmed/30244311 http://dx.doi.org/10.1007/s00401-018-1910-3 |
work_keys_str_mv | AT kvartsberghlin theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT lashleytammaryn theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT murraychristinae theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT brinkmalmgunnar theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT cullennicholasc theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT hoglundkina theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT zetterberghenrik theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT blennowkaj theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT porteliuserik theintactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT kvartsberghlin intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT lashleytammaryn intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT murraychristinae intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT brinkmalmgunnar intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT cullennicholasc intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT hoglundkina intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT zetterberghenrik intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT blennowkaj intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease AT porteliuserik intactpostsynapticproteinneurograninisreducedinbraintissuefrompatientswithfamilialandsporadicalzheimersdisease |